Pharmacological therapy for COVID-19: Where are we now and where are we going?
Background: Up to the point of writing this review, there is no scientific evidence of any effective medical therapy for coronavirus disease 2019 (COVID-19). In this review, we attempted to discuss the current summary of evidence of some medication, currently in trial for the treatment of COVID-19.
Material and Methods: We have done an electronic literature search using the following database: PubMed, Medline, Scopus and Google scholar. These databases were searched using the keywords COVID-19 and pharmacological therapy.
Results: At present, there are no well randomized controlled studies which can give evidence for most of the therapy used for COVID-19. Several medications are in trials for COVID-19, among them: 1/ chloroquine and hydroxychloroquine; 2/anti-virals oseltamivir, remdesivir, lopinavir/ritonavir and other protease inhibitors; 3/antibiotics macrolide (Azithromycin); 4/cytokine therapy interferon; 5/ humanized monoclonal antibody tocilizumab; 6/adjunct therapies vitamins C, D, and herbal medicine; 7/ COVID-19 convalescent plasma; 8/systemic steroids; 9/expected COVID-19 vaccine. We have also included some of the herbal medicines that are commonly and widely used in the Middle East, Asia as well in Sudan, (black seeds, honey and Acacia Nilotica). It is worth mentioning that these herbal medicines have shown benefits in treating other diseases, but the evidence of their benefit in COVID-19 still needs to be established.
Conclusion: Currently there is no pharmacological therapy for the COVID-19. More research and randomized clinical trials are needed to find effective therapy or vaccine against COVID-19.
COVID-19, Pharmacotherapy, herbal medicine, Sudan
1. Browning D.J. (2014) Pharmacology of Chloroquine and Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. Springer, New York, NY.
2. Keyaerts E., Vijgen L., Maes P., et al. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun, vol. 323, pp. 264-8. (DOI 10.1016/j. bbrc.2004.08.085)
3. Scuccimarri R., Sutton E. and Fitzcharles M. (2020). Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic. 2020 Jun 1;47(6):783-786.
4. Juurlink D. (2020). Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Canadian Medical Association Journal. 2020 Apr 27;192(17): E450-E453.
5. Bhimraj A., Morgan R. and Shumaker A. (2020, April). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Idsociety.org. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
6. Alhazzani W., Møller M.H., Arabi Y.M. et al. (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med Surviving Sepsis Campaign-Vol - 46-DO - 10.1007/s00134-020-06022-5JO - Intensive Care Medicine
7. Liu J., Cao R., Xu M., et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov., vol. 6, pp.1-4. (DOI 10.1038/s41421-020- 0156-0)
8. Geleris J., Sun Y. and Platt J, (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 .| N Engl J Med- 2020 Jun 18;382(25):2411-2418.
9. Valentin F. TY - BOOK-AU - Valentin, Frank-PY - 2020/03/28SP -
T1 - Azithromycin and COVID-19 History and Review-DO -10.13140/RG.2.2.33299.63524
10. Hansen M.P., et al. (2019). Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD011825. DOI: 10.1002/14651858.CD011825.pub2.
11. COVID-19 Treatment Guidelines. 2020. Author: Centre of disease control and prevention (CDC)-Therapeutic Options Under Investigation Coronavirus Disease COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation.
12. Yeming W., Dingyu Z. and Guanhua D. (2020). Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet
2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29
13. Cao B., et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covi d-19. N Engl J Med - vol. 382 no. 19-PP 1787-1799
14. Wang D., et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11): 1061-1069.doi: 10.1001/jama.2020.1585
15. Bethesda (MD), National Library of Medicine (US) (2020 Mar 12). Various combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment ofCOVID-19: A Randomized Control Trial (THDMS-COVID19). https://www.nih.gov/coronavirus
16. Cao B. et al. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub2020Mar18.(Original)PMID: 32187464
17. Fan-Ngai H.I., Kwok-Cheung L. andYuk-Keung T.E. (2020). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: Lancet. 2020 May 30;395(10238):1695-1704.
doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10
18. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
19. Kai D., – et al. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. In Proceedings of the National Academy of Sciences vol. 117, issue 17, pp.9490-9496. DOI: 10.1073/pnas.2004168117
20. WHO, author-World Health Organization-(2020)-Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
21. Arabi M.Y., Al-Omari A.A. and Mandourah M.Y. (2017). Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med., vol. 45, pp. 1683–1695.
22. Peng, Z.Y. – (2019). Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia. ClinicalTrials.gov Identifier: NCT04264533-US national library of medicine- https://clinicaltrials.gov/ct2/hom
23. : Rodrigues da Silva M, Schapochnik A, Peres Leal M, Esteves J, Bichels Hebeda C, Sandri S, et al. (2018) Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat. PLoS /ONE 13(11): e0205535. https://doi.org/10.1371/journal. pone.0205535.
24. Martineau Adrian R, Jolliffe David A, Hooper Richard L, Greenberg Lauren, Aloia John F, Bergman Peter et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data BMJ 2017; 356: i6583
25 National Institute of Allergy and Infectious Diseases (NIAID), author. NIH clinical trial of investigational vaccine for COVID-19 begins Study enrolling Seattle-based healthy adult volunteers. https://corona.kpwashingtonresearch.org/
26.Ries, J. (2020). Herbal Remedies and COVID-19: What to Know. Cassell- https://www.healthline.com/health-news/herbal-remedies-covid-19-what-to-know